Condition
Hip Osteoarthritis
Substantially less data than the knee.
Quick summary
- • Mostly uncontrolled studies
Overview
Hip osteoarthritis has well-defined standard care, so SVF research remains exploratory.
Mechanisms studied
Similar to the knee.
Human research
HHS and VAS reported in small cohorts.
Safety
Reported adverse events are mostly local — swelling, pain, or bruising at the harvest and injection sites. Infection and cell-processing quality remain the key risks to monitor.
Evidence limitations
Existing studies are limited by sample size, methodology, and follow-up, and SVF preparation differs substantially between centres, making cross-study comparison difficult.
Related research
- Level CProspective Study
Clinical use of autologous adipose-derived stromal vascular fraction cell injections for hip osteoarthritis
42 hip osteoarthritis patients received a single intra-articular injection averaging 3.8 × 10⁷ SVF cells, with at least six months of follow-up.
- 2023
- Japan
- n = 42
- Level DRetrospective Study
A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis
Chart review of 350 knee and hip osteoarthritis patients treated with autologous SVF between 2015 and 2018, reporting the proportion with improved pain and mobility.
- 2020
- Slovakia
- n = 350
Last updated: 2026-06-18 · arisa-w